Leonteq Securities AG’s NovoCure NVCR Stock Holding History

Leonteq Securities AG’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,137	Closed	-$14.7K	–	1432
2025 Q4	$14.7K	Buy	+1,137	New	+$14.6K	﹤0.01%	1152

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Leonteq Securities AG's NVCR Position: Q1 2026 in Review

Leonteq Securities AG sold out of NovoCure (NVCR) in Q1 2026, closing a stake of 1,137 shares — an estimated $14.7K sold.

Leonteq Securities AG first reported a position in NVCR in Q4 2025 and held it in 1 quarter. The position peaked at $14.7K in Q4 2025. 223 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

Leonteq Securities AG reported no remaining NovoCure position as of Q1 2026 after selling out during the quarter.
Leonteq Securities AG sold 1,137 NovoCure shares in Q1 2026, an estimated $14.7K.
Leonteq Securities AG first reported a position in NovoCure in Q4 2025 and held it in 1 quarter.
Leonteq Securities AG's NovoCure position peaked at $14.7K in Q4 2025.
223 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Leonteq Securities AG's 13F filing for Q1 2026, filed 27 Apr 2026.